Brief: Oncolytics Biotech Announces Data Identifying CEACAM6 As A Prospective Biomarker For Pelareorep In The Treatment Of Pancreatic Adenocarcinoma
27/01/2020 12:35
Jan 27 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH ANNOUNCES STATISTICALLY SIGNIFICANT
DATA
IDENTIFYING CEACAM6 AS A PROSPECTIVE PROGNOSTIC BIOMARKER FOR
PELAREOREP IN THE TREATMENT OF PANCREATIC ADENOCARCINOMA
Source text for Eikon: ID:nPn3fdtBHa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer